Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $5,457,268.11 in Stock

Posted by Geri Gentry on May 22nd, 2026

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) EVP Eliyahu Sharon Kalif sold 153,251 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the sale, the executive vice president directly owned 172,184 shares of the company’s stock, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Eliyahu Sharon Kalif also recently made the following trade(s):

On Thursday, February 26th, Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40.

Teva Pharmaceutical Industries Stock Down 0.3%

Shares of NYSE TEVA opened at $34.21 on Friday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35. The stock has a market cap of $39.33 billion, a PE ratio of 25.72, a P/E/G ratio of 3.32 and a beta of 0.86. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a 50-day moving average of $31.76 and a 200 day moving average of $30.89.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion during the quarter. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. Piper Sandler reissued an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Truist Financial increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Check Out Our Latest Analysis on TEVA

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently made changes to their positions in the stock. Global Retirement Partners LLC lifted its holdings in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after buying an additional 292 shares in the last quarter. Captrust Financial Advisors lifted its holdings in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after buying an additional 302 shares in the last quarter. Banque Cantonale Vaudoise lifted its holdings in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after buying an additional 306 shares in the last quarter. Ethic Inc. lifted its holdings in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after buying an additional 325 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.